Fatty acid metabolism in patients with PPARγ mutations

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 11, 2008, Pages 4462-4470

  Tan, Garry D ^a   Savage, David B ^c   Fielding, Barbara A ^a   Collins, Jenny ^a   Hodson, Leanne ^a   Humphreys, Sandy M ^a   O'Rahilly, Stephen ^c   Chatterjee, Krishna ^c   Frayn, Keith N ^a   Karpe, Fredrik ^a,b,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; CARBON 13; FATTY ACID; PALMITIC ACID C 13; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; CASE REPORT; CONTROLLED STUDY; FATTY ACID METABOLISM; GENE MUTATION; HUMAN; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 57349113235     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2356     Document Type: Article

References (42)

1. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J 1998 A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287
2. Ek J, Andersen G, Urhammer SA, Hansen L, Carstensen B, Borch-Johnsen K, Drivsholm T, Berglund L, Hansen T, Lithell H, Pedersen O 2001 Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) gene in relation to insulin sensitivity among glucose tolerant Caucasians. Diabetologia 44:1170-1176
3. Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M, Renn W, Häring HU 1999 The PPARγ2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 42:758-762
4. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T 2000 The Pro12Ala polymorphism in PPARγ2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271:212-216
5. Buzzetti R, Petrone A, Ribaudo MC, Alemanno I, Zavarella S, Mein CA, Maiani F, Tiberti C, Baroni MG, Vecci E, Arca M, Leonetti F, Mario UD 2004 The common PPAR-γ2 Pro12Ala variant is associated with greater insulin sensitivity. Eur J Hum Genet 12:1050-1054
6. Agarwal AK, Garg A 2002 A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 87:408-411
7. Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T 2002 PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51:3586-3590
8. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S 1999 Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883
9. Tan GD, Fielding BA, Currie JM, Humphreys SM, Desage M, Frayn KN, Laville M, Vidal H, Karpe F 2005 The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48:83-95
10. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA 2001 Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 44:2210-2219
11. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI 2000 Mechanism of troglitazone action in type 2 diabetes. Diabetes 49:827-831
12. Stumvoll M, Haring H 2002 Reduced lipolysis as possible cause for greater weight gain in subjects with the Pro12Ala polymorphism in PPARγ2? Diabetologia 45:152-153
13. Jacob S, Stumvoll M, Becker R, Koch M, Nielsen M, Loblein K, Maerker E, Volk A, Renn W, Balletshofer B, Machicao F, Rett K, Häring HU 2000 The PPARγ2 polymorphism pro12Ala is associated with better insulin sensitivity in the offspring of type 2 diabetic patients. Horm Metab Res 32:413-416
14. Stumvoll M, Häring HU 2002 Glitazones: clinical effects and molecular mechanisms. Ann Med 34:217-224
15. Tan GD, Neville MJ, Liverani E, Humphreys SM, Currie JM, Dennis L, Fielding BA, Karpe F 2006 The in vivo effects of the Pro12Ala PPARγ2 polymorphism onadipose tissue NEFA metabolism: the first use of the Oxford Biobank. Diabetologia 49:158-168
16. Monajemi H, Zhang L, Li G, Jeninga EH, Cao H, Maas M, Brouwer CB, Kalkhoven E, Stroes E, Hegele RA, Leff T 2007 Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-γ. J Clin Endocrinol Metab 92:1606-1612
17. Ludtke A, Buettner J, Wu W, Muchir A, Schroeter A, Zinn-Justin S, Spuler S, Schmidt HH, Worman HJ 2007 Peroxisome proliferator-activated receptor-γ C190S mutation causes partial lipodystrophy. J Clin Endocrinol Metab 92:2248-2255
18. Ludtke A, Buettner J, Schmidt HH, Worman HJ 2007 New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand. J Med Genet 44:e88
19. Agostini M, Schoenmakers E, Mitchell C, Szatmari I, Savage D, Smith A, Rajanayagam O, Semple R, Luan J, Bath L, Zalin A, Labib M, Kumar S, Simpson H, Blom D, Marais D, Schwabe J, Barroso I, Trembath R, Wareham N, Nagy L, Gurnell M, O'Rahilly S, Chatterjee K 2006 Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance. Cell Metab 4:303-311
20. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M, Williams RL, Umpleby AM, Thomas EL, Bell JD, Dixon AK, Dunne F, Boiani R, Cinti S, Vidal-Puig A, Karpe F, Chatterjee VK, O'Rahilly S 2003 Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ. Diabetes 52:910-917
21. Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schafer AJ 2002 Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 31:379-384
22. Garg A 2004 Acquired and inherited lipodystrophies. N Engl J Med 350:1220-1234
23. Frayn KN, Coppack SW 2001 Assessment of white adipose tissue metabolism by measurement of arteriovenous differences. Methods Mol Biol 155:269-279
24. Frayn KN, Coppack SW, Humphreys SM, Whyte PL 1989 Metabolic characteristics of human adipose tissue in vivo. Clin Sci (Lond) 76:509-516
25. Larsen OA, Lassen NA, Quaade F 1966 Blood flow through human adipose tissue determined with radioactive xenon. Acta Physiol Scand 66:337-345
26. Rådegran G 1999 Limb and skeletal muscle blood flow measurements at rest and during exercise in human subjects. Proc Nutr Soc 58:887-898
27. Evans K, Burdge GC, Wootton SA, Clark ML, Frayn KN 2002 Regulation of dietary fatty acid entrapment in subcutaneous adipose tissue and skeletal muscle. Diabetes 51:2684-2690
28. Folch J, Lees M, Sloane Stanley G 1957 A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509
29. Burdge GC, Wright P, Jones AE, Wootton SA 2000 A method for separation of phosphatidylcholine, triacylglycerol, non-esterified fatty acids and cholesterol esters from plasma by solid-phase extraction. Br J Nutr 84:781-787
30. Fielding BA, Callow J, Owen RM, Samra JS, Matthews DR, Frayn KN 1996 Postprandial lipemia: the origin of an early peak studied by specific dietary fatty acid intake during sequential meals. Am J Clin Nutr 63:36-41
31. Levy JC, Matthews DR, Hermans MP 1998 Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191-2192
32. Leroyer SN, Tordjman J, Chauvet G, Quette J, Chapron C, Forest C, Antoine B 2006 Rosiglitazone controls fatty acid cycling in human adipose tissue by means of glyceroneogenesis and glycerol phosphorylation. J Biol Chem 281:13141-13149
33. Tan GD, Debard C, Tiraby C, Humphreys SM, Frayn KN, Langin D, Vidal H, Karpe F 2003 A "futile cycle" induced by thiazolidinediones in human adipose tissue? Nat Med 9:811-812
34. Miles PD, Barak Y, He W, Evans RM, Olefsky JM 2000 Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. J Clin Invest 105:287-292
35. Auwerx J, Schoonjans K, Fruchart JC, Staels B 1996 Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. J Atheroscler Thromb 3:81-89
36. Owen KR, Donohoe M, Ellard S, Hattersley AT 2003 Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene. Diabet Med 20:823-827
37. Kelly IE, Han TS, Walsh K, Lean ME 1999 Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288-293
38. Arner P 1995 Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med 27:435-438
39. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD 2004 Splanchnic lipolysis in human obesity. J Clin Invest 113:1582-1588
40. Guo Z, Hensrud DD, Johnson CM, Jensen MD 1999 Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 48:1586-1592
41. Sekhar RV, Jahoor F, Pownall HJ, Rehman K, Gaubatz J, Iyer D, Balasubramanyam A 2005 Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. Am J Clin Nutr 81:1405-1410
42. Sekhar RV, Jahoor F, Pownall HJ, Ballantyne CM, Balasubramanyam A 2004 Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy. Curr Atheroscler Rep 6:173-179